Can CBD boost clozapine for Treatment-Resistant psychosis?

NCT ID NCT07326124

Not yet recruiting Disease control Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding cannabidiol (CBD) to the standard drug clozapine helps people with treatment-resistant psychosis. 250 participants will receive either CBD or a placebo for 12 weeks. Researchers will measure symptom changes and check safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabidiol (CBD) oral solution
What this could lead to: If it works, this could offer a new add-on option for people with psychosis who don't respond well to standard clozapine treatment.
What could go wrong: This is a phase 3 trial, but it hasn't started recruiting yet. CBD may not improve symptoms more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders treatment-refractory schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSYCHOSIS TREATMENT RESISTANT PSYCHOSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Cambridgeshire and Peterborough NHS Foundation Trust

Cambridge, United Kingdom
Charité Universitätsmedizin

Berlin, Germany
Geha Mental Health Center

Petah Tikva, Israel
Hospital General Universitario Gregorio Marañón

Madrid, Spain
Hospital Universitario Virgen del Rocío

Seville, Spain
Ludwig-Maximilian-University Munich

Munich, Germany
National and Kapodistrian University of Athens

Athens, Greece
Oxford Health NHS Foundation Trust

Oxford, United Kingdom
Psychiatric University Hospital (PUK), Zurich

Zurich, Switzerland
Shalvata Mental Health Center

Hod HaSharon, Israel
Sheba Medical Centre

Ramat Gan, Israel
Stichting Amsterdam UMC

Amsterdam, Netherlands
University Hospital Cologne

Cologne, Germany
University of Campania 'Luigi Vanvitelli'

Naples, Italy
West London NHS Trust

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.